Quality Benchmark measures will help ensure maintenance and improvement of healthcare quality and assess primary care, specialty and hospital provider, and public and private payer performance for the OHS Healthcare Benchmark Initiative.
The measures or quality benchmarks are recommended by members of the OHS HCBI Quality Council.
To view the Aligned and Core Measure Sets, click here.
To view the 2026-2030 Quality Benchmark Measures, click here.Table 1a. Commercial Quality Benchmark Values Phase 1 (2022-2025)
Phase 1 Commercial Quality Benchmark Values
Asthma Medication Ratio (Ages 5-18)
2022 Value: 79%
2023 Value: 81%
2024 Value: 83%
2025 Value: 86%
Asthma Medication Ratio (Ages 19-64)
2022 Value: 78%
2023 Value: 80%
2024 Value: 82%
2025 Value: 85%
Controlling High Blood Pressure
2022 Value: 61%
2023 Value: 63%
2024 Value: 65%
2025 Value: 68%
Glycemic Status Assessment (formerly HbA1c Control) for Patients with Diabetes: HbA1c Poor Control1
2022 Value: 27%
2023 Value: 26%
2024 Value: N/A2
2025 Value: 23%
* A lower rate indicates better performance.
**Due to significant specification changes by the National Committee for Quality Assurance (NCQA) for measurement year (MY) 2024, this measure will be reporting only for MY 2024.
Table 1b. Commercial Quality Benchmark Measures Phase 2 (2022-2025)
Phase 2 Commercial Quality Benchmark Values
Child and Adolescent Well-Care Visits
2022 Value: N/A
2023 Value: N/A
2024 Value: 80%
2025 Value: 82%
Follow-up After ED Visit for Mental Illness (7-day)
2022 Value: N/A
2023 Value: N/A
2024 Value: 64%
2025 Value: N/A*
Follow-up After Hospitalization Visit for Mental Illness (7-day)
2022 Value: N/A
2023 Value: N/A
2024 Value: 67%
2025 Value N/A**
*Due to significant specification changes by the National Committee for Quality Assurance (NCQA) for measurement year (MY) 2025, this measure will be reporting only for MY 2025.
**Due to significant specification changes by the National Committee for Quality Assurance (NCQA) for measurement year (MY) 2025, this measure will be reporting only for MY 2025.
Table 2a. Medicaid Quality Benchmarks (2022-2025) Phase 1
Phase 1 Medicaid Quality Benchmark Measures
Asthma Medication Ratio (ages 5-18)
2022 Value: 66%
2023 Value: 68%
2024 Value: 70%
2025 Value: 73%
Asthma Medication Ratio (ages 19-64)
2022 Value: 63%
2023 Value: 65%
2024 Value: 67%
2025 Value: 70%
Controlling High Blood Pressure
2022 Value: 61%
2023 Value: 63%
2024 Value: 65%
2025 Value: 68%
Glycemic Status Assessment (formerly HbA1c Control) for Patients with Diabetes: HbA1c Poor Control*
2022 Value: 37%
2023 Value: 36%
2024 Value: N/A**
2025 Value: 33%
*A lower rate indicates better performance.
** Due to significant specification changes by the National Committee for Quality Assurance (NCQA) for measurement year (MY) 2024, this measure will be reporting only for MY 2024. OHS will reevaluate the 2025 Quality Benchmark value after performance is reported for MY 2024 with potential to adjust the MY 2025 Quality Benchmark value.
Table 2b. Medicaid Quality Benchmarks Phase 2 (2022-2025)
Phase 2 Medicaid Quality Benchmark Measures
Child and Adolescent Well-Care Visits2022 Value: N/A
2023 Value: N/A
2024 Value: 66%
2025 Value: 68%
Follow-up After ED Visit for Mental Illness (7-day)2022 Value: N/A
2023 Value: N/A
2024 Value: 60%
2025 Value: N/A*
Follow-up After Hospitalization Visit for Mental Illness (7-day)
2022 Value: N/A
2023 Value: N/A
2024 Value: 53%
2025 Value: N/A**
*Due to significant specification changes by the National Committee for Quality Assurance (NCQA) for measurement year (MY) 2025, this measure will be reporting only for MY 2025.
**Due to significant specification changes by the National Committee for Quality Assurance (NCQA) for measurement year (MY) 2025, this measure will be reporting only for MY 2025.
Table 3. Medicare Advantage Quality Benchmark Values Phase 1 (2022-2025)
Phase 1 Medicare Advantage Quality Benchmark Measures
Controlling High Blood Pressure
2022 Value: 73%
2023 Value: 75%
2024 Value: 77%
2025 Value: 80%
Glycemic Status Assessment (formerly HbA1c Control) for Patients with Diabetes: HbA1c Poor Control*
2022 Value: 20%
2023 Value: 18%
2024 Value: N/A
2025 Value: 15%**
*A lower rate indicates better performance.
**Due to significant specification changes by the National Committee for Quality Assurance (NCQA) for measurement year (MY) 2024, this measure will be reporting only for MY 2024. OHS will re-evaluate the 2025 Quality Benchmark value after performance is reported for MY 2024 with the potential to adjust the MY 2025 Quality Benchmark value.
Table 4. Statewide Quality Benchmark Values Phase 2 (2022-2025)
Phase 2 Statewide Quality Benchmark Values
Obesity Equity Measure**
2022 Value: N/A
2023 Value: N/A
2024 Value: 1.42
2025 Value: 1.38
**This measure is the ratio of statewide obesity rates for Black, non-Hispanic population and White, non-Hispanic population. A rate of 1 indicates that the statewide obesity rates for both populations are identical.
In addition to reporting statewide performance on the Obesity Equity Measure, OHS will also report the three-year rolling average obesity rate for the Black, non-Hispanic population against target values of 37% for 2024 and 35% for 2025.
2022-2025 Quality benchmark measures
Quality Benchmark Measure
Asthma Medication Ratio
Steward 1
NCQA
Description
Percentage of patients 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Controlling High Blood Pressure
Steward 1
NCQA
Description
Percentage of patients 18 to 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90 mmHg) during the measurement year
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Glycemic Status Assessment for Patients with Diabetes (formerly Hemoglobin A1c [HbA1c] Control for Patients with Diabetes: HbA1c Poor Control)
Steward 1
NCQA
Description
Percentage of patients 18-75 years of age with diabetes (types 1 and 2) whose most recent glycemic status (hemoglobin a1c [HbA1c] or glucose management indicator [GMI]) was >9.0% during the measurement year.
Levels of Measurement
State, Market, Payer, Advanced Network
Asthma Medication Ratio
Steward 1
NCQA
Description
Percentage of patients 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Controlling High Blood Pressure
Steward 1
NCQA
Description
Percentage of patients 18 to 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90 mmHg) during the measurement year
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Glycemic Status Assessment for Patients with Diabetes (formerly Hemoglobin A1c [HbA1c] Control for Patients with Diabetes: HbA1c Poor Control)
Steward 1
NCQA
Description
Percentage of patients 18-75 years of age with diabetes (types 1 and 2) whose most recent glycemic status (hemoglobin a1c [HbA1c] or glucose management indicator [GMI]) was >9.0% during the measurement year.
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Child and Adolescent WellCare Visits
Steward 1
NCQA
Description
Percentage of members 3–21 years of age who had at least one comprehensive well-care visit with a primary care provider or an OB/GYN practitioner during the measurement year
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Follow-up After Emergency Department (ED) Visit for Mental Illness (7-day)
Steward 1
NCQA
Description
Percentage of ED visits for members 6 years of age and older with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness within 7 days of the ED visit
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Follow-up After Hospitalization Visit for Mental Illness (7-day)
Steward 1
NCQA
Description
Percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter, or partial hospitalization with a mental health practitioner within 7 days of discharge
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Obesity Equity Measure
Steward 1
CT OHS (using data from BRFSS)
Description
A ratio of statewide obesity rates for the Black, non-Hispanic population and the White, non-Hispanic population
Levels of Measurement
State
Child and Adolescent WellCare Visits
Steward 1
NCQA
Description
Percentage of members 3–21 years of age who had at least one comprehensive well-care visit with a primary care provider or an OB/GYN practitioner during the measurement year
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Follow-up After Emergency Department (ED) Visit for Mental Illness (7-day)
Steward 1
NCQA
Description
Percentage of ED visits for members 6 years of age and older with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness within 7 days of the ED visit
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Follow-up After Hospitalization Visit for Mental Illness (7-day)
Steward 1
NCQA
Description
Percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter, or partial hospitalization with a mental health practitioner within 7 days of discharge
Levels of Measurement
State, Market, Payer, Advanced Network
Quality Benchmark Measure
Obesity Equity Measure
Steward 1
CT OHS (using data from BRFSS)
Description
A ratio of statewide obesity rates for the Black, non-Hispanic population and the White, non-Hispanic population
Levels of Measurement
State
2026-2030 Quality benchmark measures
Colorectal Cancer Screening
2026 Value: 77.7
2027 Value: 77.7
2028 Value: 77.7
2029 Value: 77.7
2030 Value: 77.7
Controlling High Blood Pressure
2026 Value: 72.0
2027 Value: 72.9
2028 Value: 73.9
2029 Value: 74.8
2030 Value: 75.8
Glycemic Status > 9.0%
2026 Value: 21.3
2027 Value: 20.5
2028 Value: 19.8
2029 Value: 19.2
2030 Value: 18.5
Immunizations for Adolescents
2026 Value: 28.0
2027 Value: 30.3
2028 Value: 32.8
2029 Value: 35.5
2030 Value: 38.4
Prenatal and Postpartum Care: Timeliness of Prenatal Care
2026 Value: 87.7
2027 Value: 89.2
2028 Value: 90.7
2029 Value: 92.3
2030 Value: 93.9
Prenatal and Postpartum Care: Postpartum Care
2026 Value: 90.4
2027 Value: 91.2
2028 Value: 92.1
2029 Value: 93.0
2030 Value: 93.9
REL Data Completeness
2026 Value: TBD
2027 Value: TBD
2028 Value: TBD
2029 Value: TBD
2030 Value: TBD
Colorectal Cancer Screening
2026 Value: 31.6
2027 Value: 33.1
2028 Value: 34.7
2029 Value: 36.4
2030 Value: 38.1
Controlling High Blood Pressure
2026 Value: 71.4
2027 Value: 72.4
2028 Value: 73.4
2029 Value: 74.4
2030 Value: 75.4
Glycemic Status > 9.0%
2026 Value: 27.8
2027 Value: 26.3
2028 Value: 24.9
2029 Value: 23.6
2030 Value: 22.4
Immunizations for Adolescents
2026 Value: 39.8
2027 Value: 41.9
2028 Value: 44.1
2029 Value: 46.3
2030 Value: 48.7
Prenatal and Postpartum Care: Timeliness of Prenatal Care
2026 Value: 93.7
2027 Value: 93.7
2028 Value: 93.7
2029 Value: 93.7
2030 Value: 93.7
Prenatal and Postpartum Care: Postpartum Care
2026 Value: 89.0
2027 Value: 89.2
2028 Value: 89.5
2029 Value: 89.7
2030 Value: 90.0
REL Data Completeness
2026 Value: TBD
2027 Value: TBD
2028 Value: TBD
2029 Value: TBD
2030 Value: TBD
Colorectal Cancer Screening
2026 Value: 75.2
2027 Value: 76.4
2028 Value: 77.6
2029 Value: 78.8
2030 Value: 80.0
Controlling High Blood Pressure
2026 Value: 76.8
2027 Value: 77.6
2028 Value: 78.4
2029 Value: 79.2
2030 Value: 80.0
Glycemic Status > 9.0%
2026 Value: 15.6
2027 Value: 14.3
2028 Value: 13.1
2029 Value: 12.0
2030 Value: 11.0
REL Data Completeness
2026 Value: TBD
2027 Value: TBD
2028 Value: TBD
2029 Value: TBD
2030 Value: TBD
Aligned Measure Sets
The aligned measure set is a set of measures from which OHS requests insurers select measures for use in new value-based contracts.
